

Notice of Allowability	Application No. 09/701,711	Applicant(s) Y DE BASSOLS, CARLOTA VINALS
	Examiner Padmavathi v Baskar	Art Unit 1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to 2/17/04.
2. The allowed claim(s) is/are 61-71 and have been renumbered as 1-11 respectively.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____

DETAILED ACTION

Amendment

1. Applicant's after amendment filed on 2/17/04 is acknowledged.

Status of Claims

2. Claims 61 and 64 have been amended.

New claims 69-71 have been added.

Claims 61-71 are pending in the application.

3. In view of amendment to the claims and the arguments of record the rejection of claims 61-64 and 66-68 under 35 U.S.C. 112, first paragraph is withdrawn.
4. In view of amendment to the claims and the arguments of record, the rejection of claims 61-64 and 66-68 under 35 U.S.C. 112, first paragraph, scope of enablement is withdrawn.
5. In view of amendment to the claims and the arguments of record, the rejection of claims 61-64 under 35 U.S.C. 102(b) as being anticipated by Bartos et al 1988(J.Infec.Dis, 158; 761-765) is withdrawn. This rejection is withdrawn because Bartos et al do not disclose a recombinant polypeptide comprising the amino acid sequence, SEQ.ID.NO: 2.
6. In view of amendment to the claims and the arguments of record, the rejection of claims 61- 64 and 66-68 under 35 U.S.C. 102(b) as being anticipated by Helminen et al 1994 (J.Infec.Dis, 170; 867-872) is withdrawn. This rejection is withdrawn because Helminen et al 1994 do not disclose a recombinant polypeptide comprising the amino acid sequence, SEQ.ID.NO: 2.

Art Unit: 1645

7. The instant claims define a novel recombinant polypeptide SEQ.ID.NO: 2 from *Moraxella catarrhalis*. This purified recombinant BASB027polypeptide has been shown to bind to a pool of human sera from children infected with various clinical isolates M catarrhalis by Western blot analysis. Therefore, this antigen is useful for diagnostic assays for detecting the infection caused by various clinical strains of *Moraxella catarrhalis*.

Remarks

8. Claims 61-71 are allowed and have been renumbered as 1-11 respectively.

Conclusion

9. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform to the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The RightFax number for submission of before-final amendments is (703) 872-9306. The RightFax number for submission of after-final amendments is (703) 872-9307.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Padma Baskar Ph.D.

3/14/04

Lynette R. F. Smith
LYNETTE R. F. SMITH
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600